筛查乳腺X线与超声检出的导管原位癌长期监测:与第二乳腺癌相关的因素
该单中心回顾性研究纳入2004年7月至2011年12月手术治疗的814例筛查检出导管原位癌女性,比较乳腺X线检出组(627例)与超声检出组(187例)的生存结局。中位随访7年,两组无病生存率无显著差异(P=0.21,5年无病生存率分别为94.9%和96.5%)。乳腺X线检出组中 higher nuclear grade 和致密乳腺与第二乳腺癌相关,超声检出组中 human epidermal growth factor receptor 2 阳性与第二乳腺癌相关。
要点
- 筛查X线与超声检出的导管原位癌患者无病生存率无显著差异(P=0.21)。
- X线检出组中,中级别核(HR 5.7)和高级别核(HR 8.0)及致密乳腺(HR 3.5)与第二乳腺癌相关。
- 超声检出组中,human epidermal growth factor receptor 2 阳性与第二乳腺癌相关(HR 9.2)。
核心结论
- 筛查检出导管原位癌患者接受治疗后,无病生存率不因筛查检出方法不同而存在差异。
研究设计与样本
- 单中心回顾性研究,纳入2004年7月至2011年12月因筛查检出导管原位癌接受手术的女性814例,中位年龄47岁(范围25-81岁)。
- 乳腺X线检出组627例,超声检出组187例;中位随访7年(四分位距5-8年)。
- 评估总生存率和无病生存率,采用多因素Cox比例风险回归分析第二乳腺癌(浸润癌或导管原位癌)相关因素。
诊断标准与关键数值
- 随访期间共发现52例第二乳腺癌(6.4%,52/814),其中同侧26例、对侧26例;乳腺X线检出组44例,超声检出组8例。
- 总体5年总生存率和无病生存率分别为100%和95.3%;5年无病生存率乳腺X线检出组94.9% vs 超声检出组96.5%(P=0.21)。
- 乳腺X线检出组:中级别核 vs 低级别核 HR 5.7(95%CI 1.3-24.3,P=0.02);高级别核 vs 低级别核 HR 8.0(95%CI 1.9-34.2,P=0.01);致密乳腺 HR 3.5(95%CI 1.1-11.4,P=0.04)。
- 超声检出组:human epidermal growth factor receptor 2 阳性 HR 9.2(95%CI 2.2-38.5,P=0.002)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The relationship between method of breast cancer screening (mammography or US) and survival outcome in patients with screening-detected ductal carcinoma in situ (DCIS) has not been determined. Purpose To investigate whether different methods of breast cancer screening are associated with different survival outcomes in patients with screening-detected DCIS and to evaluate clinical-pathologic and imaging factors associated with second breast cancer. Materials and Methods We retrospectively identified women who underwent surgery to treat DCIS initially detected with screening mammography or US between July 2004 and December 2011 in a single institution. Overall survival (OS) and disease-free survival (DFS) were assessed. Factors associated with second breast cancer (invasive carcinoma or DCIS) were found with multivariable Cox proportional hazards regression analysis. Subgroups were analyzed according to screening method. Results A total of 814 women (median age, 47 years; age range, 25-81 years) were included; 627 underwent treatment for screening mammography-detected DCIS (mammography-detected group), and 187 underwent treatment for screening US-detected DCIS (US-detected group). During follow-up (median, 7 years; interquartile range, 5-8 years), 26 ipsilateral and 26 contralateral second breast cancers (6.4%, 52 of 814) were found, with 44 in the mammography-detected group and eight in the US-detected group. The overall 5-year OS and DFS rates were 100% and 95.3%, respectively. DFS rates did not differ according to screening method (P = .21, 5-year DFS rates were 94.9% in the mammography-detected group and 96.5% in the US-detected group). In the mammography-detected group, higher nuclear grade (intermediate grade: hazard ratio [HR], 5.7; 95% confidence interval [CI]: 1.3, 24.3; P = 0.02) (high grade: HR, 8.0; 95% CI: 1.9, 34.2; P = .01) and dense breast (HR, 3.5; 95% CI: 1.1, 11.4; P = 0.04) were associated with second breast cancer. In the US-detected group, human epidermal growth factor receptor 2 positivity was associated with second breast cancer (HR, 9.2; 95% CI: 2.2, 38.5; P = .002). Conclusion Disease-free survival of patients who underwent treatment for screening-detected ductal carcinoma in situ (DCIS) did not differ according to screening detection method. In patients with screening mammography-detected DCIS, higher nuclear grade and dense breast were associated with second breast cancer, and in patients with screening US-detected DCIS, human epidermal growth factor 2 positivity was associated with second breast cancer. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Fowler in this issue.
引用
- Choi SH, Choi JS, Han BK, et al. Long-term Surveillance of Ductal Carcinoma in Situ Detected with Screening Mammography versus US: Factors Associated with Second Breast Cancer. Radiology. 2019. PMID: 31038406. doi:10.1148/radiol.2019181844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。